These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23668273)

  • 1. Should patients with systemic sclerosis-related pulmonary arterial hypertension be anticoagulated?
    Nikpour M; Stevens W; Proudman SM; Buchbinder R; Prior D; Zochling J; Williams T; Gabbay E; Nandurkar H
    Intern Med J; 2013 May; 43(5):599-603. PubMed ID: 23668273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Warfarin in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. A Bayesian approach to evaluating treatment for uncommon disease.
    Johnson SR; Granton JT; Tomlinson GA; Grosbein HA; Le T; Lee P; Seary ME; Hawker GA; Feldman BM
    J Rheumatol; 2012 Feb; 39(2):276-85. PubMed ID: 22247353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol.
    Calderone A; Stevens W; Prior D; Nandurkar H; Gabbay E; Proudman SM; Williams T; Celermajer D; Sahhar J; Wong PK; Thakkar V; Dwyer N; Wrobel J; Chin W; Liew D; Staples M; Buchbinder R; Nikpour M
    BMJ Open; 2016 Dec; 6(12):e011028. PubMed ID: 27932335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH).
    Sobanski V; Launay D; Hachulla E; Humbert M
    Curr Rheumatol Rep; 2016 Feb; 18(2):10. PubMed ID: 26841964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of warfarin on survival in scleroderma-associated pulmonary arterial hypertension (SSc-PAH) and idiopathic PAH. Belief elicitation for Bayesian priors.
    Johnson SR; Granton JT; Tomlinson GA; Grosbein HA; Hawker GA; Feldman BM
    J Rheumatol; 2011 Mar; 38(3):462-9. PubMed ID: 21159827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL).
    Preston IR; Roberts KE; Miller DP; Sen GP; Selej M; Benton WW; Hill NS; Farber HW
    Circulation; 2015 Dec; 132(25):2403-11. PubMed ID: 26510696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension.
    Morrisroe K; Stevens W; Huq M; Prior D; Sahhar J; Ngian GS; Celermajer D; Zochling J; Proudman S; Nikpour M;
    Arthritis Res Ther; 2017 Jun; 19(1):122. PubMed ID: 28576149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary arterial hypertension in the setting of scleroderma is different than in the setting of lupus: A review.
    Bazan IS; Mensah KA; Rudkovskaia AA; Adonteng-Boateng PK; Herzog EL; Buckley L; Fares WH
    Respir Med; 2018 Jan; 134():42-46. PubMed ID: 29413506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scleroderma lung disease, variation in screening, diagnosis and treatment practices between rheumatologists and respiratory physicians.
    Mangat P; Conron M; Gabbay E; Proudman SM;
    Intern Med J; 2010 Jul; 40(7):494-502. PubMed ID: 19460060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome measures in pulmonary arterial hypertension associated with systemic sclerosis.
    Kowal-Bielecka O; Delcroix M; Vonk-Noordegraaf A; Hoeper MM; Naeije R
    Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v39-41. PubMed ID: 18784140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospects for improving outcomes in systemic sclerosis-related pulmonary hypertension.
    Thakkar V; Nikpour M; Stevens WM; Proudman SM
    Intern Med J; 2015 Mar; 45(3):248-54. PubMed ID: 25735576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.
    McLaughlin V; Humbert M; Coghlan G; Nash P; Steen V
    Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii25-31. PubMed ID: 19487219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Update on Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: a Review of the Current Literature.
    Sundaram SM; Chung L
    Curr Rheumatol Rep; 2018 Feb; 20(2):10. PubMed ID: 29488016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival.
    Humbert M; Yaici A; de Groote P; Montani D; Sitbon O; Launay D; Gressin V; Guillevin L; Clerson P; Simonneau G; Hachulla E
    Arthritis Rheum; 2011 Nov; 63(11):3522-30. PubMed ID: 21769843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary arterial hypertension associated with systemic sclerosis.
    Mathai SC; Hassoun PM
    Expert Rev Respir Med; 2011 Apr; 5(2):267-79. PubMed ID: 21510736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study).
    Wigley FM; Lima JA; Mayes M; McLain D; Chapin JL; Ward-Able C
    Arthritis Rheum; 2005 Jul; 52(7):2125-32. PubMed ID: 15986394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension.
    Rosato E; Molinaro I; Borghese F; Rossi C; Pisarri S; Salsano F
    J Rheumatol; 2010 Dec; 37(12):2531-9. PubMed ID: 20810512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anticoagulation therapy in pulmonary arterial hypertension].
    Akagi S; Kusano KF
    Nihon Rinsho; 2008 Nov; 66(11):2174-8. PubMed ID: 19051739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH.
    Clements PJ; Tan M; McLaughlin VV; Oudiz RJ; Tapson VF; Channick RN; Rubin LJ; Langer A;
    Ann Rheum Dis; 2012 Feb; 71(2):249-52. PubMed ID: 21998119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors of mortality and 2-year survival analysis of systemic sclerosis with pulmonary arterial hypertension in Thailand.
    Foocharoen C; Nanagara R; Kiatchoosakun S; Suwannaroj S; Mahakkanukrauh A
    Int J Rheum Dis; 2011 Aug; 14(3):282-9. PubMed ID: 21816025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.